Actavia Life Sciences, Inc. is a biotechnology company, which engages in the development of therapeutics for the treatment of leukemia and lymphoma diseases. The company is headquartered in New York City, New York and currently employs 1 full-time employees. The company went IPO on 2014-03-28. The firm is engaged in developing therapeutics to address the unmet need that exists for acute myeloid leukemia (AML), and other forms of leukemia and lymphoma. AML is generally a disease of older adults. The company develops small molecule drug candidates targeting the LSD1 gene, which controls pathways underlying the etiology of AML subtypes. Its RASP-201 is a novel, orally dosed, selective reversible inhibitor of lysine specific demethylase (LSD1), a pathway that blocks differentiation and confers a poor prognosis to AML. RASP-201 when dosed orally shows in vivo therapeutic utility in murine (mouse) models of AML. Its primary indication is AML which may be fatal within weeks to months.
Follow-Up Questions
What is Actavia Life Sciences Inc (RASP)'s P/E Ratio?
The P/E ratio of Actavia Life Sciences Inc is N/A
What is the price performance of RASP stock?
The current price of RASP is 0.01, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Actavia Life Sciences Inc?
Actavia Life Sciences Inc belongs to Biotechnology industry and the sector is Health Care
What is Actavia Life Sciences Inc market cap?
Actavia Life Sciences Inc's current market cap is $7.7
Is Actavia Life Sciences Inc a buy, sell, or hold?
According to wall street analysts, 0 analysts have made analyst ratings for Actavia Life Sciences Inc, including 0 strong buy, 0 buy, 0 hold, 0 sell, and 0 strong sell
